Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?
Department of Oral Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
Richard L
RL
Wynn
D019386:Alendronate / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D019379:Teriparatide; D014807:Vitamin D; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D002118:Calcium; D019386:Alendronate